{"nct_id":"NCT04305041","title":"Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)","status":"COMPLETED","status_verified_date":"2025-08","start_date":"2020-06-26","start_date_type":"ACTUAL","primary_completion_date":"2025-08-25","primary_completion_date_type":"ACTUAL","completion_date":"2025-08-25","completion_date_type":"ACTUAL","phases":["PHASE1","PHASE2"],"tickers":["MRK"]}